# Troglitazone in Treating Patients With Liposarcoma

> **NCT00003058** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 85 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** troglitazone

## Key facts

- **NCT ID:** NCT00003058
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 2000-01
- **Final completion:** 2000-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2017-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003058, "Troglitazone in Treating Patients With Liposarcoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00003058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*